Foundayo (orforglipron)
FDA approved for obesity on 2026-04-01; Q2 2026 revenue $98M; type 2 diabetes submitted in the US.
The numbers
What it is
Orforglipron, an oral small-molecule GLP-1 receptor agonist taken without food or water restrictions. It is the first oral obesity drug from Lilly and competes directly with Novo Nordisk's oral semaglutide.↗ source
Why it matters to the stock. Foundayo extends Lilly's incretin franchise into the oral market, where pricing and volume could differ sharply from injectables.
News
Foundayo ACHIEVE-4: MACE-4 non-inferiority met vs insulin glargine, not significant
Lilly reported detailed ACHIEVE-4 results for Foundayo on September 30, 2026, showing the oral GLP-1 met non-inferiority against insulin glargine on major adverse cardiovascular events.
UK MHRA approves Foundayo (orforglipron) for weight management and type 2 diabetes
The UK Medicines and Healthcare products Regulatory Agency authorised Lilly's oral GLP-1 Foundayo for weight management and for type 2 diabetes on August 10, 2026.
Medicare GLP-1 Bridge starts July 1 with $50 monthly copay for Zepbound and Foundayo
Eligible Medicare Part D patients can get Zepbound and Foundayo for weight management for $50 a month under the Medicare GLP-1 Bridge program, which started July 1, 2026.
Medicare GLP-1 Bridge coverage for Foundayo and Zepbound starts July 1
Lilly said Medicare coverage for Foundayo and the Zepbound KwikPen for weight management began on July 1, 2026 under the Medicare GLP-1 Bridge program, with a $50 monthly cost to patients after prior authorization.
FDA approves Foundayo, Lilly's oral GLP-1 pill, for adults with obesity
The FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist taken without food or water restrictions, for adults with obesity and for adults with overweight who have at least one weight-related condition.